Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Coherus BioSciences Inc CHRS

Healthcare Biotechnology
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and... see more

Recent & Breaking News (NDAQ:CHRS)

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma

GlobeNewswire June 5, 2023

Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY(TM), a HUMIRA® biosimilar, available to patients

GlobeNewswire June 1, 2023

Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY(TM) (adalimumab-aqvh) Launching in July 2023

GlobeNewswire June 1, 2023

Coherus Announces U.S. Launch of UDENYCA® Autoinjector

GlobeNewswire May 22, 2023

Coherus Prices Public Offering of Common Stock

GlobeNewswire May 16, 2023

Coherus Announces Proposed Public Offering of Common Stock

GlobeNewswire May 15, 2023

Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

GlobeNewswire May 8, 2023

Coherus BioSciences to Present at Upcoming Investor Conferences in May

GlobeNewswire May 4, 2023

Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023

GlobeNewswire May 1, 2023

Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 27, 2023

Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results

GlobeNewswire March 6, 2023

FDA Approves UDENYCA® Autoinjector

GlobeNewswire March 6, 2023

Coherus BioSciences to Present at Upcoming Investor Conferences in March

GlobeNewswire March 1, 2023

Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

GlobeNewswire February 28, 2023

Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

GlobeNewswire February 15, 2023

Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services

GlobeNewswire February 13, 2023

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire February 3, 2023

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

GlobeNewswire January 9, 2023

Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2023

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

GlobeNewswire December 25, 2022